Based on the above considerations, we aimed to examine the therapeutic effect of Lac-β-CyD on hepatomegaly in the NPC model mice (Npc1−/− mice), and to evaluate its safety in wild type (WT) mice. This evidence concerns the gene NPC1 and nasopharyngeal carcinoma.